Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patients, 2002-2009g

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

467 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-08-31

Study Completion Date

2012-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of the study is to assess the relationship (both crude and adjusted) between voriconazole utilization and the development of non-melanoma skin cancer among adult patients who received a lung or heart/lung transplant and were continuously enrolled in a large U.S. commercial health plan.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Voriconazole as Prophylaxis for Liver Transplant Recipients

NCT00177788

Fungemia Mycoses

COMPLETED

Voriconazole Prophylaxis Against Aspergillosis in Lung Transplant Recipients

NCT00177827

Post Lung Transplantation

COMPLETED

Voriconazole as Prophylactic Therapy in Lung Transplant Recipients

NCT00455364

Infection

TERMINATED PHASE4

An Assessment of Voriconazole Pharmacokinetics and Pharmacogenetics in Liver Transplant Recipients - Pilot Study

NCT00371605

Liver Transplant Fungal Infection

TERMINATED

The Influence of CYP2C19 Polymorphisms on the Safety and Efficacy of Voriconazole

NCT04547335

Adverse Drug Reactions

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

N/A. All patients aged 18 or older who received a lung or heart/lung transplant from January 1, 2002 through December 31, 2009 in the MarketScan database were sampled.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-Melanoma Skin Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Any Voriconazole

voriconazole (Vfend)

Intervention Type DRUG

Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.

No Voriconazole

no voriconazole (Vfend)

Intervention Type OTHER

Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

voriconazole (Vfend)

Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.

Intervention Type DRUG

no voriconazole (Vfend)

Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Vfend Vfend

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 18 or older who received a lung or heart/lung transplant from January 1, 2002 through December 31, 2009 in the MarketScan database will be initially included in the study.

Exclusion Criteria

* Patients who are younger than 18 years of age and who are not enrolled for at least 180 days before and 180 days after the date of transplant will be excluded.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No